サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1782004

消化器治療薬市場：薬剤タイプ別、剤形別、用途別、流通チャネル別、国別、地域別：世界産業分析、市場規模、市場シェア、2025年～2032年予測

Gastrointestinal Therapeutics Market, By Medication Type, By Drug Type, By Dosage Form, By Application, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

出版日
ページ情報
英文 284 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
消化器治療薬市場：薬剤タイプ別、剤形別、用途別、流通チャネル別、国別、地域別：世界産業分析、市場規模、市場シェア、2025年～2032年予測
出版日: 2025年07月01日
発行: AnalystView Market Insights
ページ情報: 英文 284 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

消化器治療薬市場規模は2024年に402億911万米ドルとなり、2025年から2032年にかけてCAGR 5.50%で拡大

消化器治療薬市場-市場力学

生物学的製剤の進歩が治療効果と採用を強化

生物学的製剤の進歩は、より的を絞った効果的な治療を提供することで、消化管障害の治療を一変させました。これらの治療は、免疫系を特異的に調節することで効果を発揮し、従来の薬剤よりも炎症を抑制して症状を改善します。クローン病や潰瘍性大腸炎に広く使用されている生物学的製剤であるアッヴィのヒュミラ（アダリムマブ）は、その標的を絞ったアプローチにより患者の予後を大幅に改善し、この成功例を示しています。バイオシミラー（生物学的製剤）の導入は、これらの治療薬をより身近で手頃なものにし、消化器治療薬市場における生物学的製剤の全体的な普及を後押しすることで、この成長をさらに後押ししています。

例えば

2024年3月、ファイザーは一般的な生物学的製剤のバイオシミラーを発売し、消化器治療薬市場におけるプレゼンスを拡大した。これらのバイオシミラー医薬品は、オリジナルの生物学的製剤と同等の有効性と安全性を有しながら、より低コストであるため、特にコストに敏感な市場において、より多くの患者層が先進的な治療にアクセスしやすくなっています。

2023年9月、ジョンソン・エンド・ジョンソンは炎症性腸疾患の治療を目的とした革新的な生物学的製剤を発表しました。同社の新製品は、より効果的に炎症を抑えるために特定の免疫経路を標的とすることに焦点を当て、長期的な疾患管理と転帰を改善する可能性のある新たな選択肢を患者に提供します。

こうした継続的な技術革新と生物学的製剤へのアクセス拡大は、消化器治療薬市場の大幅な成長と患者転帰の改善を促進すると期待されています。

消化器治療薬市場-主要インサイト

当社のリサーチアナリストが共有した分析によると、世界市場は予測期間（2025-2032年）に約5.50%のCAGRで毎年成長すると予測されています。

薬剤タイプ別では、ブランド薬が2024年に最大市場シェアを占めると予測

薬剤タイプ別では、生物学的製剤／バイオシミラーが2024年の主要薬剤タイプです。

剤形別では、経口剤が2024年の主要剤形です。

用途別では、胃食道逆流症（GERD）が2024年の主要用途でした。

流通チャネル別では、病院薬局が2024年の主要流通チャネルです。

地域別では、北米が2024年の売上高でトップ

消化器治療薬市場-セグメンテーション分析：

世界の消化器治療薬市場は、薬物タイプ、薬剤タイプ、剤形、用途、流通チャネル、地域に基づいて細分化されます。

市場は薬の種類によって2つのカテゴリーに分けられます。ブランド品とジェネリック医薬品です。市場を独占しているのはブランド品分野です。臨床的に検証された確立された薬剤に対する医師の強い嗜好、積極的なマーケティングとブランド認知による高い採用率、クローン病、潰瘍性大腸炎、過敏性腸症候群などの複雑な消化器疾患をターゲットとした革新的な製剤の入手が可能なためです。加えて、特許保護と規制上の独占権により、特に高度で専門的な治療に対する需要が高い先進地域では、特定の治療分野におけるジェネリック医薬品の浸透が制限されています。

市場は用途別にクローン病、胃食道逆流症（GERD）、過敏性腸症候群（IBS）、潰瘍性大腸炎、その他の5つのカテゴリーに分類されます。胃食道逆流症（GERD）は、消化器治療薬市場において支配的な用途セグメントを占めています。これは、特に先進地域における世界の有病率の高さと、しばしば長期または生涯にわたる管理を必要とする慢性的な疾患であることが主な原因です。プロトンポンプ阻害薬（PPI）やH2受容体拮抗薬が広く使用されていることに加え、肥満、食生活の乱れ、ストレスなどの生活習慣に関連した要因による診断率の増加が、この市場におけるGERDの優位性をさらに高めています。加えて、強力な医薬品パイプラインとGERDをターゲットとした継続的な製品革新が、GERD市場のトップシェアに大きく貢献しています。

消化器治療薬市場-地理的洞察

2024年の予測期間中、北米が世界の消化器治療薬市場を独占しています。

北米は、高度なヘルスケアインフラと高い医療費により、消化器治療薬市場をリードし、最大のシェアを占めています。同地域では、GERD、IBS、クローン病などの消化器疾患が大きな負担となっており、効果的な治療薬に対する需要が高まっています。大手製薬企業の存在、確立された規制の枠組み、革新的な医薬品への幅広いアクセスが、市場の成長をさらに促進しています。認知度の高さ、早期診断、有利な償還政策もこの地域の優位性に寄与しています。北米では米国が主要な牽引役であり、継続的な研究開発投資と新規治療オプションの急速な導入に支えられています。

アジア太平洋は、2024年の予測期間中、消化器治療薬市場で最も高いCAGRを記録すると予測されます。

アジア太平洋は、消化器疾患の有病率が増加している大規模かつ高齢化した人口に牽引され、消化器治療薬市場で最も急成長している地域です。急速な都市化、ライフスタイルの変化、食生活のシフトが、GERDやIBSなどの疾患の罹患率上昇に寄与しています。ヘルスケア投資の拡大、政府のイニシアティブ、医療へのアクセス拡大が、中国、インド、韓国などの国々の市場開拓を支えています。未開拓の可能性があり、手頃な価格で高品質の治療薬に対する需要が高まっていることから、製薬会社はますますこの地域に注目しています。認知度の向上とヘルスケアインフラの整備が、この地域の成長をさらに加速させています。

消化器治療薬市場-競合情勢：

消化器治療薬市場は競争が激しく、革新的な治療法の研究開発・商業化に積極的に取り組む世界的・地域的企業が複数存在しています。AbbVie Inc.、武田薬品工業、ジョンソン・エンド・ジョンソン、ファイザー、アストラゼネカなどの主要企業は、クローン病、潰瘍性大腸炎、GERD、IBSなどの主要な消化器疾患をターゲットとした強力な製品ポートフォリオで市場を独占しています。これらの企業は、戦略的提携、M&A、広範な研究開発に注力することで、市場での地位を維持し、治療薬の提供を拡大しています。

同時に、より優れた有効性と安全性を約束する最先端の生物学的製剤や低分子の開発に取り組む新興バイオテクノロジー企業の参入も急増しています。バイオシミラーやジェネリック医薬品の存在感が高まるにつれ、特に新興国市場では価格競争も激化しています。各社は、世界展開の拡大、規制当局の承認取得、先進的ドラッグデリバリーシステムの導入などにリソースを投入し、先手を打っています。一言で言えば、技術革新、強力なパイプライン、地域情勢別拡大が、この市場の競合情勢を形成する原動力となっています。

目次

第1章 消化器治療薬市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 消化器治療薬の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 消化器系治療薬産業の調査

  • PESTEL分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 消化器系治療薬市場：高まる地政学的緊張の影響

  • COVID-19パンデミックの影響
  • ロシア・ウクライナ戦争の影響
  • 中東紛争の影響

第6章 消化器系治療薬市場情勢

  • 消化器治療薬市場シェア分析、2024年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 消化器治療薬市場- 医薬品タイプ別

  • 概要
    • 医薬品タイプ別セグメントシェア分析
    • ブランド
    • ジェネリック医薬品

第8章 消化器治療薬市場- 薬剤タイプ別

  • 概要
    • 薬剤タイプ別セグメントシェア分析
    • 制酸剤
    • 制吐剤
    • 下痢止め
    • 抗潰瘍剤
    • 抗生物質
    • 生物製剤/バイオシミラー
    • 下剤
    • プロトンポンプ阻害剤（PPI）
    • その他の薬剤タイプ

第9章 消化器治療薬市場- 剤形別

  • 概要
    • 剤形別セグメントシェア分析
    • 経口
    • 非経口

第10章 消化器系治療薬市場- 用途別

  • 概要
    • 用途別セグメントシェア分析
    • クローン病
    • 胃食道逆流症（GERD）
    • 過敏性腸症候群（IBS）
    • 潰瘍性大腸炎
    • その他

第11章 消化器治療薬市場- 流通チャネル別

  • 概要
    • 流通チャネル別セグメントシェア分析
    • 病院薬局
    • 小売薬局
    • オンライン薬局

第12章 消化器治療薬市場-地域

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • オランダ
    • スウェーデン
    • ロシア
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋の主要メーカー
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • インドネシア
    • タイ
    • フィリピン
    • その他
  • ラテンアメリカ（LATAM）
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東およびアフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第13章 主要ベンダー分析- 消化器系治療薬業界

  • 競合ベンチマーキング
    • Competitive Dashboard
    • Competitive Positioning
  • 企業プロファイル
    • Abbott Laboratories
    • AbbVie Inc.
    • AstraZeneca Plc
    • Bayer AG
    • Biogen Inc.
    • Boehringer Ingelheim International GmbH
    • Boston Scientific Corp.
    • Cipla
    • Eisai Co. Ltd.
    • Eli Lilly and Co.
    • Evoke Pharma Inc.
    • GlaxoSmithKline Plc
    • Johnson and Johnson Services Inc.
    • Merck and Co. Inc.
    • Novartis AG
    • Olympus Corp.
    • Ovesco Endoscopy AG
    • Pfizer Inc.
    • Salix Pharmaceuticals Inc.
    • Takeda Pharmaceutical Co. Ltd.
    • UCB SA
    • Others

第14章 アナリストの全方位展望

目次
Product Code: ANV5444

REPORT HIGHLIGHT

Gastrointestinal Therapeutics Market size was valued at US$ 40,209.11 Million in 2024, expanding at a CAGR of 5.50% from 2025 to 2032.

The Gastrointestinal Therapeutics Market is all about producing, and distributing medications aimed at tackling issues related to the digestive system. This includes a variety of conditions like Crohn's disease, ulcerative colitis, GERD, IBS, and various infections that can affect the gastrointestinal (GI) tract. The market features a broad spectrum of treatments, such as antacids, biologics, anti-diarrheal, proton pump inhibitors, laxatives, and antibiotics, which can be administered through both oral and injectable forms. The growing demand in this sector is largely fueled by the increasing rates of GI diseases, lifestyle related digestive problems, and the latest advancements in targeted therapies and biologics. Both branded and generic medications play a role in this market, which is primarily supplied through hospitals, retail outlets, and online pharmacies.

Gastrointestinal Therapeutics Market- Market Dynamics

Advancements in biologics enhance therapeutic effectiveness and adoption

Advancements in biologics have transformed the treatment of gastrointestinal disorders by offering more targeted and effective therapies. These treatments work by specifically modulating the immune system, which helps control inflammation and manage symptoms better than traditional drugs. AbbVie's Humira (adalimumab), a biologic drug widely used for Crohn's disease and ulcerative colitis, exemplifies this success with its targeted approach significantly improving patient outcomes. The introduction of biosimilar versions has further supported this growth by making these therapies more accessible and affordable, boosting the overall adoption of biologic therapies in the gastrointestinal therapeutics market.

for instance,

In March 2024, Pfizer expanded its presence in the GI therapeutics market by launching biosimilar versions of popular biologics. These biosimilars offer comparable efficacy and safety to original biologics but at a lower cost, making advanced treatments more accessible to a wider patient population, especially in cost sensitive markets.

In September 2023, Johnson & Johnson introduced innovative biologic therapies aimed at treating inflammatory bowel diseases. Their new products focus on targeting specific immune pathways to reduce inflammation more effectively, providing patients with new options that could potentially improve long-term disease management and outcomes.

These continuous innovations and expanded access to biologics are expected to drive significant growth and improved patient outcomes in the gastrointestinal therapeutics market.

Gastrointestinal Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.50% over the forecast period (2025-2032)

Based on medication type segmentation, branded was predicted to show maximum market share in the year 2024

Based on drug type segmentation, biologics/ biosimilars was the leading drug type in 2024

Based on dosage form segmentation, oral was the leading dosage form in 2024

Based on application segmentation, gastroesophageal reflux disease (GERD) was the leading application in 2024

Based on distribution channel segmentation, hospital pharmacies was the leading distribution channel in 2024

On the basis of region, North America was the leading revenue generator in 2024

Gastrointestinal Therapeutics Market- Segmentation Analysis:

The global gastrointestinal therapeutics market is segmented on the basis of medication type, drug type, dosage form, application, distribution channel, and region.

The market is divided into two categories based on medication type: Branded, and Generics. The Branded sector dominates the market. Due to strong physician preference for established, clinically validated drugs, high adoption driven by aggressive marketing and brand recognition, and the availability of innovative formulations targeting complex GI conditions such as Crohn's disease, ulcerative colitis, and irritable bowel syndrome. Additionally, patent protections and regulatory exclusivity have limited the penetration of generics in certain therapeutic segments, especially in developed regions where there is a higher demand for advanced and specialized treatments.

The market is divided into five categories based on application: crohn's disease, gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), ulcerative colitis, others. Gastroesophageal Reflux Disease (GERD) represents the dominating application segment in the gastrointestinal therapeutics market. This is largely attributed to its high global prevalence, especially in developed regions, and the chronic nature of the condition, which often requires long-term or lifelong management. The widespread use of proton pump inhibitors (PPIs) and H2 receptor antagonists, coupled with increasing diagnosis rates due to lifestyle-related factors such as obesity, poor diet, and stress, further fuels the dominance of GERD in this market. Additionally, strong pharmaceutical pipelines and continuous product innovation targeting GERD contribute significantly to its leading market share.

Gastrointestinal Therapeutics Market- Geographical Insights

North America dominates the global gastrointestinal therapeutics market during the forecast period in 2024.

North America leads the gastrointestinal therapeutics market, accounting for the largest share due to its advanced healthcare infrastructure and high healthcare spending. The region experiences a significant burden of gastrointestinal disorders such as GERD, IBS, and Crohn's disease, which drives strong demand for effective therapies. The presence of major pharmaceutical companies, a well-established regulatory framework, and widespread access to innovative drugs further enhance market growth. High awareness levels, early diagnosis, and favourable reimbursement policies also contribute to the region's dominance. The United States is the primary driver within North America, supported by ongoing R&D investments and rapid adoption of novel treatment options.

Asia Pacific is estimated to register the highest CAGR in the gastrointestinal therapeutics market during the forecast period in 2024.

Asia-Pacific is the fastest growing region in the gastrointestinal therapeutics market, driven by a large and aging population with increasing prevalence of GI disorders. Rapid urbanization, lifestyle changes, and dietary shifts are contributing to a higher incidence of diseases such as GERD and IBS. Growing healthcare investments, government initiatives, and expanding access to medical care are supporting market development across countries like China, India, and South Korea. Pharmaceutical companies are increasingly focusing on this region due to its untapped potential and rising demand for affordable, high-quality therapeutics. Improved awareness and healthcare infrastructure are further accelerating growth across the region.

Gastrointestinal Therapeutics Market- Competitive Landscape:

The gastrointestinal therapeutics market is highly competitive, with the presence of several global and regional players actively engaged in research, development, and commercialization of innovative treatments. Key companies such as AbbVie Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Pfizer Inc., and AstraZeneca dominate the market with strong product portfolios targeting major GI disorders like Crohn's disease, ulcerative colitis, GERD, and IBS. These players focus on strategic collaborations, mergers & acquisitions, and extensive R&D to maintain their market positions and expand their therapeutic offerings.

At the same time, there's a surge of emerging biotech firms stepping into the ring, working on cutting-edge biologics and small molecules that promise better efficacy and safety. The growing presence of biosimilars and generic drugs is also ramping up price competition, especially in developing markets. Companies are pouring resources into expanding their global reach, securing regulatory approvals, and rolling out advanced drug delivery systems to stay ahead of the game. In a nutshell, innovation, a strong pipeline, and geographic expansion are the driving forces shaping the competitive landscape of this market.

Recent Developments:

In February 2025, Zydus Lifesciences received U.S. FDA approval for the production Ibuprofen and Famotidine tablets. These tablets were designed to treat rheumatoid arthritis and osteoarthritis while reducing the risk of upper GI ulcers. This approval aimed to broaden Zydus's GI portfolio addressing the burden of peptic ulcer cases

In April 2025, Allergan plc completed the acquisition of Viral Burn, a privately-held biotechnology company focused on developing novel therapeutics for gastrointestinal diseases. The acquisition adds Viral Burn's lead asset, VB-201, a first in class, oral, non-systemic antiviral therapy for the treatment of norovirus gastroenteritis, to Allergan's pipeline

In April 2021, Teva Pharmaceuticals USA launched its 1000 mg generic version of Casana (mesalamine) suppository for treating adults with active ulcerative proctitis in the U.S. The introduction of this affordable generic alternative increases treatment accessibility and positions Teva strongly in the GI market by offering cost-effective options. It also helps the company capitalize on the growing demand for ulcerative colitis treatments amid rising prevalence

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corp.
  • Cipla
  • Eisai Co. Ltd.
  • Eli Lilly and Co.
  • Evoke Pharma Inc.
  • GlaxoSmithKline Plc
  • Johnson and Johnson Services Inc.
  • Merck and Co. Inc.
  • Novartis AG
  • Olympus Corp.
  • Ovesco Endoscopy AG
  • Pfizer Inc.
  • Salix Pharmaceuticals Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • UCB SA
  • Others

GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY MEDICATION TYPE- MARKET ANALYSIS, 2019 - 2032

  • Branded
  • Generics

GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Antacids
  • Antiemetics
  • Antidiarrheals
  • Antiulcer agents
  • Antibiotics
  • Biologics/ biosimilars
  • Laxatives
  • Proton pump inhibitors (PPIs)
  • Other drug types

GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY DOSAGE FORM- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Parenteral

GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Crohn's disease
  • Gastroesophageal reflux disease (GERD)
  • Irritable Bowel Syndrome (IBS)
  • Ulcerative colitis
  • Others

GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Gastrointestinal Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Gastrointestinal Therapeutics Market Snippet by Medication Type
    • 2.1.2. Gastrointestinal Therapeutics Market Snippet by Drug Type
    • 2.1.3. Gastrointestinal Therapeutics Market Snippet by Dosage Form
    • 2.1.4. Gastrointestinal Therapeutics Market Snippet by Application
    • 2.1.5. Gastrointestinal Therapeutics Market Snippet by Distribution Channel
    • 2.1.6. Gastrointestinal Therapeutics Market Snippet by Country
    • 2.1.7. Gastrointestinal Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. Gastrointestinal Therapeutics Key Market Trends

  • 3.1. Gastrointestinal Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Gastrointestinal Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Gastrointestinal Therapeutics Market Opportunities
  • 3.4. Gastrointestinal Therapeutics Market Future Trends

4. Gastrointestinal Therapeutics Industry Study

  • 4.1. PESTEL Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Gastrointestinal Therapeutics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Gastrointestinal Therapeutics Market Landscape

  • 6.1. Gastrointestinal Therapeutics Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Gastrointestinal Therapeutics Market - By Medication Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Medication Type, 2024 & 2032 (%)
    • 7.1.2. Branded
    • 7.1.3. Generics

8. Gastrointestinal Therapeutics Market - By Drug Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
    • 8.1.2. Antacids
    • 8.1.3. Antiemetics
    • 8.1.4. Antidiarrheals
    • 8.1.5. Antiulcer agents
    • 8.1.6. Antibiotics
    • 8.1.7. Biologics/ biosimilars
    • 8.1.8. Laxatives
    • 8.1.9. Proton pump inhibitors (PPIs)
    • 8.1.10. Other drug types

9. Gastrointestinal Therapeutics Market - By Dosage Form

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Dosage Form, 2024 & 2032 (%)
    • 9.1.2. Oral
    • 9.1.3. Parenteral

10. Gastrointestinal Therapeutics Market - By Application

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 10.1.2. Crohn's disease
    • 10.1.3. Gastroesophageal reflux disease (GERD)
    • 10.1.4. Irritable Bowel Syndrome (IBS)
    • 10.1.5. Ulcerative colitis
    • 10.1.6. Others

11. Gastrointestinal Therapeutics Market - By Distribution Channel

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 11.1.2. Hospital pharmacies
    • 11.1.3. Retail pharmacies
    • 11.1.4. Online pharmacies

12. Gastrointestinal Therapeutics Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Gastrointestinal Therapeutics Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Gastrointestinal Therapeutics Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.18. Rest of Europe
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.18.3. Rest of the Europe Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.18.4. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.18.5. Rest of the Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.18.6. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.18.7. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Gastrointestinal Therapeutics Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Gastrointestinal Therapeutics Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Gastrointestinal Therapeutics Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Gastrointestinal Therapeutics Industry

  • 13.1. Competitive Benchmarking
    • 13.1.1. Competitive Dashboard
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. Abbott Laboratories
    • 13.2.2. AbbVie Inc.
    • 13.2.3. AstraZeneca Plc
    • 13.2.4. Bayer AG
    • 13.2.5. Biogen Inc.
    • 13.2.6. Boehringer Ingelheim International GmbH
    • 13.2.7. Boston Scientific Corp.
    • 13.2.8. Cipla
    • 13.2.9. Eisai Co. Ltd.
    • 13.2.10. Eli Lilly and Co.
    • 13.2.11. Evoke Pharma Inc.
    • 13.2.12. GlaxoSmithKline Plc
    • 13.2.13. Johnson and Johnson Services Inc.
    • 13.2.14. Merck and Co. Inc.
    • 13.2.15. Novartis AG
    • 13.2.16. Olympus Corp.
    • 13.2.17. Ovesco Endoscopy AG
    • 13.2.18. Pfizer Inc.
    • 13.2.19. Salix Pharmaceuticals Inc.
    • 13.2.20. Takeda Pharmaceutical Co. Ltd.
    • 13.2.21. UCB SA
    • 13.2.22. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us